TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01836432

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRINOX
Description: FOLFIRINOX consisting of Oxaliplatin 85 mg/m\^2 IV over 2 hours; Irinotecan 180 mg/m\^2 IV over 90 minutes; Leucovorin 400 mg/m\^2 IV over 2 hours; Fluorouracil 2.4 g/m\^2 IV over 46 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: FOLFIRINOX consisting of Oxaliplatin 85 mg/m\^2 IV over 2 hours; Irinotecan 180 mg/m\^2 IV over 90 minutes; Leucovorin 400 mg/m\^2 IV over 2 hours; Fluorouracil 2.4 g/m\^2 IV over 46 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFIRINOX
Description: FOLFIRINOX consisting of Oxaliplatin 85 mg/m\^2 IV over 2 hours; Irinotecan 180 mg/m\^2 IV over 90 minutes; Leucovorin 400 mg/m\^2 IV over 2 hours; Fluorouracil 2.4 g/m\^2 IV over 46 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX
Description: FOLFIRINOX consisting of Oxaliplatin 85 mg/m\^2 IV over 2 hours; Irinotecan 180 mg/m\^2 IV over 90 minutes; Leucovorin 400 mg/m\^2 IV over 2 hours; Fluorouracil 2.4 g/m\^2 IV over 46 hours

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Algenpantucel-L Immunotherapy
Description: Algenpantucel-L Immunotherapy (HAPa) consisting of 300 Million HAPa cells given by intradermal injection

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Algenpantucel-L Immunotherapy
Description: Algenpantucel-L Immunotherapy (HAPa) consisting of 300 Million HAPa cells given by intradermal injection

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU Chemoradiation
Description: 5-FU Chemoradiation consisting of 5-FU continuous IV infusion of 200-250 mg/m\^2/day given 5-7 days each week over 5.5 weeks concurrently with external beam radiation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 5-FU Chemoradiation
Description: 5-FU Chemoradiation consisting of 5-FU continuous IV infusion of 200-250 mg/m\^2/day given 5-7 days each week over 5.5 weeks concurrently with external beam radiation

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: 5-FU Chemoradiation
Description: 5-FU Chemoradiation consisting of 5-FU continuous IV infusion of 200-250 mg/m\^2/day given 5-7 days each week over 5.5 weeks concurrently with external beam radiation
Study: NCT01599624

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Resilience Training System (SRTS)
Description: SRTS training provides both cognitive learning and training in a scientifically-designed stress resilience training approach designed to minimize the adverse effects of stress and also enhance its positive effects. In summary, the SRTS training comprises: (1) Cognitive rules and mental exercises based on expert knowledge and research; (2) Biofeedback stress control exercises based on proven HRV (Heart Rate Variability) algorithms developed by the Institute of HeartMath; and (3) E-Learning presentation of games and simulations to motivate younger trainees. The training is designed to familiarize participants with the iPad and the SRTS program. Participants will be told how to use the system and how often to use the system. SRTS program participants will each be assigned an iPad to take home with them and practice the techniques for a period of two months.
Study: NCT01836432

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 5-FU Chemoradiation
Description: 5-FU Chemoradiation consisting of 5-FU continuous IV infusion of 200-250 mg/m\^2/day given 5-7 days each week over 5.5 weeks concurrently with external beam radiation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 given intravenously over 30 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 given intravenously over 30 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 given intravenously over 30 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1000 mg/m\^2 given intravenously over 30 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine consisting of 825 mg/m\^2 PO BID M-F concurrently with external beam radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine consisting of 825 mg/m\^2 PO BID M-F concurrently with external beam radiation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: Capecitabine consisting of 825 mg/m\^2 PO BID M-F concurrently with external beam radiation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabine consisting of 825 mg/m\^2 PO BID M-F concurrently with external beam radiation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-Paclitaxel
Description: Nab-Paclitaxel 125 mg/m\^2 given intravenously over 30-40 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Nab-Paclitaxel 125 mg/m\^2 given intravenously over 30-40 minutes
Study: NCT01599624

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR)
Description: Progressive muscle relaxation is the systematic tensing and relaxing of 16 different muscle groups, starting with one's toes and ending with one's head (Jacobson, 1938; Conrad \& Roth, 2007). PMR users are instructed to inhale as they tense the muscles and exhale as they release the tension. Participants will participate in a two-hour PMR training. PMR participants will be given iPADs with a video recording that guides the user through working each muscle group while instructing them to focus on positive thoughts and feelings and breathing techniques. PMR program participants will each be assigned an iPad to take home with them and practice the techniques for a period of two months.
Study: NCT01836432

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-Paclitaxel
Description: Nab-Paclitaxel 125 mg/m\^2 given intravenously over 30-40 minutes
Study: NCT01864603

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Universal ART in a streamlined care model
Description: immediate ART start for all HIV+ in community with streamlined care
Study: NCT01836432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Nab-Paclitaxel 125 mg/m\^2 given intravenously over 30-40 minutes
Study: NCT02287974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stem cell infusion
Description: Unique stem cell infusion of the randomized group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stem cell infusion
Description: Unique stem cell infusion of the randomized group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stem cell infusion
Description: Unique stem cell infusion of the randomized group

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Stem cell infusion
Description: Unique stem cell infusion of the randomized group
Study: NCT00272909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: piclozotan low dose
Description: Continuous IV infusion over a period of up to 72 hours of piclozotan

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Continuous IV infusion over a period of up to 72 hours of placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: piclozotan high dose
Description: Continuous IV infusion over a period of up to 72 hours of piclozotan
Study: NCT02006342

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Glargine
Study: NCT01864603

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Universal ART in a streamlined care model
Description: immediate ART start for all HIV+ in community with streamlined care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Annual Community Health Campaigns
Description: HIV and multi-disease testing for all community members

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted PrEP and Targeted testing interventions
Study: NCT02006342

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Regular Insulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular Insulin
Study: NCT02474212

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Study: NCT04217187

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation
Description: Upper extremity neuromuscular electrical stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Electrical Stimulation
Description: Sensory only upper extremity electrical stimulation
Study: NCT02855528

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tin Filter
Study: NCT01489566

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tyroserleutide for injection ,chemotherapy(mitomycin, and Fluorouracil )
Description: mitomycin(10mg)+Fluorouracil(1.0g),through the chemoradiative pump,every cycle,5-30 minites; Tyroserleutide for injection(30mg) ,through the micro infusion pump,every cycle,3-5 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: the placebo ,chemotherapy(mitomycin, and Fluorouracil )
Description: mitomycin(10mg)+Fluorouracil(1.0g),through the chemoradiative pump,every cycle,5-30 minites; the placebo(30mg) ,through the micro infusion pump,every cycle,3-5 days
Study: NCT00893724

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Neutral pills with no medicinal effect
Description: Neutral pills with no medicinal effect

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Inosine; Tocopherols, Tocotrienol, CoQ10 combination capsule; Niacinamide SR; Viatmin C; N-acetyl Cysteine; Complete Multivitamin with all minerals
Description: Inosine \[SR\] - 1\[500mg\] tablet bid Tocopherols \[200IU\], Tocotrienol \[10mg\], CoQ10 \[50mg\] - combination capsule bid Sustained Release Niacinamide - 1 \[750mg\] tablet bid Vitamin C - 1 \[1000mg\] sustained release tablet bid N-acetyl Cysteine - 1 \[600mg\] sustained release tablet qd Complete Multivitamin with all minerals - 1 tablet (sustained release) bid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inosine; Tocopherol, Tocotrienol, CoQ10 combination capsule; Niacinamide; Vitamin C; N-acetyl Cysteine; Complete Multivitamin with all minerals; Minocycline
Description: Inosine \[SR\] - 1 \[500mg\] tablet bid Tocopherol \[200IU\], Tocotrienol \[10mg\], CoQ10 \[50mg\] combination capsule bid Sustained Release Niacinamide 1 \[750mg\] tablet bid Vitamin C 1 \[1000mg\] sustained release tablet bid N-acetyl Cysteine 1 \[600mg\] sustained release tablet qd Complete Multivitamin with all minerals - 1 tablet (sustained release) bid Minocycline 1 \[50mg\] tablet qd
Study: NCT02820311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-4208 175 mcg
Description: via nebulizer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TD-4208 700 mcg
Description: via nebulizer

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for TD-4208
Description: via nebulizer
Study: NCT01864603

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Baseline community-based HIV and multi-disease testing
Description: HIV and multi-disease testing for all community members at baseline only
Study: NCT02820311

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin 400 mg
Description: oral
Study: NCT00334022

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: enfuvirtide
Description: 1ml BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enfuvirtide
Description: 1ml BID
Study: NCT01577186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone ER
Description: Participants will receive paliperidone ER tablet in flexible dose range of 3 to 12 milligram per day (mg/day) orally once daily up to Week 12 as per Investigator's discretion.
Study: NCT03287219

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylene Blue MMX 25 mg modified release tablets
Description: Methylene Blue MMX 25 mg modified release tablets administered with a full dose regimen of a 4-L PEG-based bowel cleansing preparation.
Study: NCT02441296

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Formula with lactose

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Formula with maltodextrins
Study: NCT01090661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mipomersen sodium
Description: 200 mg of mipomersen intravenous (IV) (single dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mipomersen sodium
Description: 200 mg of mipomersen subcutaneous (SC) (single dose)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: moxifloxacin hydrochloride (Avelox®)
Description: 400 mg of moxifloxacin intravenous (IV) single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo intravenous (IV) single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo intravenous (IV) single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: placebo subcutaneous (SC) single dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: placebo subcutaneous (SC) single dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo subcutaneous (SC) single dose
Study: NCT02446899

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anifrolumab
Description: Intravenous infusion (IV)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous infusion (IV)
Study: NCT04663659

Intervention type: OTHER
Intervention: no intervention
Description: no intervention

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT02165267

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01
Description: Administered IV in 100 mL of normal saline (Sodium Chloride for Injection 0.9%, USP) or administered SC by needle and syringe injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01
Description: Administered IV in 100 mL of normal saline (Sodium Chloride for Injection 0.9%, USP) or administered SC by needle and syringe injection.
Study: NCT02738983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib (trade name: Tarceva®) or Icotinib (trade name: Conmana®)
Description: Erlotinib (trade name: Tarceva®) (150mg oral daily) or Icotinib (trade name: Conmana®) (125mg oral three times a day).

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: Concurrent radiotherapy total dose 60-66 Gy in 2 Gy fractions. One fraction per day, and 5 fractions per week.
Study: NCT01118351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib malate
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TdT-mediated dUTP nick end labeling assay
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: light microscopy
Description: Correlative studies
Study: NCT02165267

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01
Description: Administered IV in 100 mL of normal saline (Sodium Chloride for Injection 0.9%, USP) or administered SC by needle and syringe injection.
Study: NCT01118351

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02413112

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Whole-body resistance training in the University gym that is supervised by researchers.~Training once per week, Training twice per week, Training thrice per week.
Study: NCT02165267

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01
Description: Administered IV in 100 mL of normal saline (Sodium Chloride for Injection 0.9%, USP) or administered SC by needle and syringe injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC01
Description: Administered IV in 100 mL of normal saline (Sodium Chloride for Injection 0.9%, USP) or administered SC by needle and syringe injection.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: SC placebo for VRC01
Description: Sterile, buffered aqueous solution of 25 mM Sodium Citrate, 50 mM Sodium Chloride, 150 mM L-Arginine Hydrochloride, 10% Dextran 40, and 0.005% Polysorbate 80 at pH 5.8 administered SC by needle and syringe injection

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: IV placebo for VRC01
Description: Sodium Chloride for Injection 0.9%, USP administered IV in 100 mL of normal saline (Sodium Chloride for Injection 0.9%, USP)
Study: NCT02413112

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Whole-body resistance training in the University gym that is supervised by researchers.~Training once per week, Training twice per week, Training thrice per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Whole-body resistance training in the University gym that is supervised by researchers.~Training once per week, Training twice per week, Training thrice per week.
Study: NCT01757353

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: BASICS motivational interview
Study: NCT00746980

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: efalizumab
Description: 1 mg/kg subcutaneously once weekly for 48 weeks, following an initial conditioning dose of 0.7 mg/kg at week 0.
Study: NCT03569709

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: Progressive sub-threshold aerobic exercise

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Rest
Description: No structured exercise.
Study: NCT01757353

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BASICS plus normative enhancement motivational interview

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Self-directed: Information only
Study: NCT03569709

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Stretching
Description: Gentle progressive upper and lower extremity stretching program
Study: NCT02731209

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: urinary catheter
Study: NCT03587454

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Teleglaucoma
Description: Subjects are evaluated through a teleglaucoma protocol then by physical presence in a glaucoma clinic
Study: NCT01437852

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: StrataGraft Skin Tissue
Study: NCT03114514

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP
Description: PRP will be injected subcutaneously around the eyes at three different time points with one-month interval
Study: NCT03500900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg
Description: Acute administration of Vildagliptin, 50 mg.
Study: NCT00436345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: analgesia in medical and post-surgical Intensive Care Unit subjects requiring mechanical ventilation
Study: NCT03500900

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Acute administration of placebo tablet
Study: NCT01934556

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab 0.3 mg intravitreal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab 0.3 mg intravitreal injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab 0.3 mg intravitreal injection

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Guided Laser Photocoagulation
Study: NCT03694496

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: peer-led theory-based intervention group
Description: We plan to select 2-8 peer leaders in S2 students within each school in the intervention group. A total of 25-48 peer leaders will be selected and trained in this study.~An experienced behavioural scientist will train the peer leaders through lectures, workshops, and individual counselling.~A total of 6 hours training (3 hours per day x 2 days) will be conducted during weekends. Peer leaders will practice in groups, and only those who pass the evaluation are allowed to conduct peer-led interventions. We will record the performance and give specific feedback to each peer leader.
Study: NCT04601948

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth Activity Intervention
Description: Eligible participants will receive a Fitbit activity monitor and access to our mHealth physical activity intervention for 6 weeks. The intervention will include regular motivational messages to encourage activity, a social media thread to provide social support, and a series of fun virtual walking races.
Study: NCT00436345

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: conventional sedation in medical and post-surgical Intensive Care Unit subjects requiring mechanical
Study: NCT01614314

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Preceptorship
Description: After attending a lecture and a video on the dressing of the tunneled central venous catheter, the subjects performed the procedure on a manikin simulator, with the aid of a nurse preceptorship, lasting one hour.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Auto-instructional guide
Description: After attending a lecture and a video on the dressing of the tunneled central venous catheter, the subjects performed the procedure on a manikin simulator, with the aid of an auto-instructional guide, lasting one hour.
Study: NCT00922948

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Cryoneedles and one temperature probe are inserted under endoscopic and sonographic guidance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Thermal injury is the predominant mechanism of action of RFA. A high-frequency alternating current emitted from the exposed noninsulated portion of the electrode generates frictional heat, agitating ions in the tissue surrounding the tip of the needle.